Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
暂无分享,去创建一个
Alexandra Aubry | L. Fisher | A. Aubry | S. Matrat | E. Cambau | Xiao-Su Pan | C. Lascols | Xiaohui Pan | Emmanuelle Cambau | Stephanie Matrat | Romain Roth Dit Bettoni | Céline Corbel | Christine Lascols | Jean-Yves Driot | L Mark Fisher | J. Driot | Romain Roth Dit Bettoni | R. Roth | C. Corbel | X. Pan | Dit Bettoni | D. Bettoni
[1] E. Denamur,et al. In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid. , 2006, The Journal of antimicrobial chemotherapy.
[2] J. Crouzet,et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones , 1994, Molecular microbiology.
[3] K. Köhrer,et al. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. , 1999, FEMS immunology and medical microbiology.
[4] K. Gould,et al. Cleavable-Complex Formation by Wild-Type and Quinolone-Resistant Streptococcus pneumoniae Type II Topoisomerases Mediated by Gemifloxacin and Other Fluoroquinolones , 2002, Antimicrobial Agents and Chemotherapy.
[5] C. Soussy,et al. Analysis of the mutations involved in fluoroquinolone resistance of in vivo and in vitro mutants of Escherichia coli. , 1998, Microbial drug resistance.
[6] P. Heisig,et al. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus. , 1999, The Journal of antimicrobial chemotherapy.
[7] D. Hooper,et al. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV , 1997, Antimicrobial agents and chemotherapy.
[8] A. Khodursky,et al. Topoisomerase IV is a target of quinolones in Escherichia coli. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[9] D. Hooper,et al. Quinolone antimicrobial agents , 1993 .
[10] L. Fisher,et al. Streptococcus pneumoniae DNA Gyrase and Topoisomerase IV: Overexpression, Purification, and Differential Inhibition by Fluoroquinolones , 1999, Antimicrobial Agents and Chemotherapy.
[11] M. Tanaka,et al. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae. , 1999, The Journal of antimicrobial chemotherapy.
[12] C. Chan,et al. A RAPID HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR CEFEPIME, CEFPIROME AND MEROPENEM , 1998 .
[13] V. Jarlier,et al. Novel Gyrase Mutations in Quinolone-Resistant and -Hypersusceptible Clinical Isolates of Mycobacterium tuberculosis: Functional Analysis of Mutant Enzymes , 2006, Antimicrobial Agents and Chemotherapy.
[14] A. Zanchi,et al. Microbiological features of acute bacterial conjunctivitis in a central Italian area. , 2008, The new microbiologica.
[15] A. G. de la Campa,et al. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins. , 2000, Microbial drug resistance.
[16] H. Hiasa,et al. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. , 1998, Biochimica et biophysica acta.
[17] L. Fisher,et al. DNA Gyrase and Topoisomerase IV Are Dual Targets of Clinafloxacin Action in Streptococcus pneumoniae , 1998, Antimicrobial Agents and Chemotherapy.
[18] J. Ambler,et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae , 1996, Antimicrobial agents and chemotherapy.
[19] K. Ward,et al. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. , 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[20] K. Hiramatsu,et al. Primary Targets of Fluoroquinolones inStreptococcus pneumoniae , 1999, Antimicrobial Agents and Chemotherapy.
[21] P. Heisig,et al. Impact of gyrA and parCMutations on Quinolone Resistance, Doubling Time, and Supercoiling Degree of Escherichia coli , 1999, Antimicrobial Agents and Chemotherapy.
[22] D. Ince,et al. Mechanisms and Frequency of Resistance to Gatifloxacin in Comparison to AM-1121 and Ciprofloxacin inStaphylococcus aureus , 2001, Antimicrobial Agents and Chemotherapy.
[23] Xilin Zhao,et al. Gatifloxacin Activity against Quinolone-Resistant Gyrase: Allele-Specific Enhancement of Bacteriostatic and Bactericidal Activities by the C-8-Methoxy Group , 1999, Antimicrobial Agents and Chemotherapy.
[24] J. Yamagishi,et al. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli , 1986, Molecular and General Genetics MGG.
[25] I. Morrissey,et al. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition , 1994, Antimicrobial Agents and Chemotherapy.
[26] L. Fisher,et al. Grepafloxacin, a Dimethyl Derivative of Ciprofloxacin, Acts Preferentially through Gyrase in Streptococcus pneumoniae: Role of the C-5 Group in Target Specificity , 2002, Antimicrobial Agents and Chemotherapy.
[27] J. Ambler,et al. Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro , 2000, Antimicrobial Agents and Chemotherapy.
[28] A. Maxwell,et al. Novel quinolone resistance mutations of the Escherichia coli DNA gyrase A protein: enzymatic analysis of the mutant proteins , 1991, Antimicrobial Agents and Chemotherapy.
[29] P. Heisig,et al. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli , 1996, Antimicrobial agents and chemotherapy.
[30] D. Wigley,et al. Cloning of the DNA gyrase genes under tac promoter control: overproduction of the gyrase A and B proteins. , 1990, Gene.
[31] D. Gilbert,et al. Phenotypic Resistance of Staphylococcus aureus, Selected Enterobacteriaceae, and Pseudomonas aeruginosa after Single and Multiple In Vitro Exposures to Ciprofloxacin, Levofloxacin, and Trovafloxacin , 2001, Antimicrobial Agents and Chemotherapy.
[32] D. Hoban,et al. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims. , 2002, The Journal of antimicrobial chemotherapy.
[33] D. Hooper,et al. Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection: Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin , 2005, Antimicrobial Agents and Chemotherapy.
[34] J. Crouzet,et al. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases , 1996, Antimicrobial agents and chemotherapy.
[35] L. Fisher,et al. Dual activity of fluoroquinolones against Streptococcus pneumoniae. , 2003, The Journal of antimicrobial chemotherapy.
[36] D. Ince,et al. Topoisomerase Targeting with and Resistance to Gemifloxacin in Staphylococcus aureus , 2003, Antimicrobial Agents and Chemotherapy.
[37] L. Gutmann,et al. Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid , 1993, Antimicrobial Agents and Chemotherapy.
[38] D. Hooper,et al. Mutations in Topoisomerase IV and DNA Gyrase of Staphylococcus aureus: Novel Pleiotropic Effects on Quinolone and Coumarin Activity , 1998, Antimicrobial Agents and Chemotherapy.
[39] I. Morrissey,et al. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones. , 2000, The Journal of antimicrobial chemotherapy.
[40] M. Gellert,et al. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[41] L. Fisher,et al. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones , 1997, Antimicrobial agents and chemotherapy.
[42] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[43] D. Hooper,et al. Mechanisms of action and resistance of older and newer fluoroquinolones. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] D. Ince,et al. Activity of and Resistance to Moxifloxacin in Staphylococcus aureus , 2003, Antimicrobial Agents and Chemotherapy.
[45] MECHANISMS OF QUINOLONE RESISTANCE , 2003 .
[46] R. Manzo,et al. Engineering the Specificity of Antibacterial Fluoroquinolones: Benzenesulfonamide Modifications at C-7 of Ciprofloxacin Change Its Primary Target in Streptococcus pneumoniae from Topoisomerase IV to Gyrase , 2000, Antimicrobial Agents and Chemotherapy.
[47] Katsuhiko Hayashi,et al. Contribution of the 8-Methoxy Group to the Activity of Gatifloxacin against Type II Topoisomerases of Streptococcus pneumoniae , 2003, Antimicrobial Agents and Chemotherapy.
[48] D. Ince,et al. Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Garenoxacin (BMS-284756, T-3811ME), a New Desfluoroquinolone , 2002, Antimicrobial Agents and Chemotherapy.
[49] T. Gootz,et al. Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents , 1989, Antimicrobial Agents and Chemotherapy.
[50] S. Nakamura,et al. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli , 1990, Antimicrobial Agents and Chemotherapy.
[51] Kenichi Sato,et al. In Vitro and In Vivo Antibacterial Activities of DK-507k, a Novel Fluoroquinolone , 2003, Antimicrobial Agents and Chemotherapy.
[52] J. Crouzet,et al. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus , 1995, Antimicrobial agents and chemotherapy.